Article
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.
Genes and immunity - 1 Sept 2011
Vosslamber S, van der Voort L F, van den Elskamp I J, Heijmans R, Aubin C, Uitdehaag B M J, Crusius J B A, van der Pouw Kraan T C T M, van der PouwKraan T C T M, Comabella M, Montalban X, Hafler D A, De Jager P L, Killestein J, Polman C H, Verweij C L
Abstract excerpt
Interferon-β (IFNβ) therapy is effective in approximately half of the patients with relapsing-remitting multiple sclerosis (RRMS). Clinical non-responders were characterized by an increased expression of IFN response genes before the start of therapy, and a lack of a pharmacologically induced increase in IFN response gene activity. Because Interferon Regulatory Factor 5 (IRF5) is a master regulator of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.